Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality.
Kevin Outterson and colleagues outline a model to address access, conservation, and innovation of antibiotics.
Boston University School of Law, Boston, Massachusetts, United States of America.|Chatham House Centre for Global Health Security, London, United Kingdom.|DRIVE-AB, Innovative Medicines Initiative, Geneva, Switzerland.
Kevin
K
Outterson
Oslo University Hospital, Oslo, Norway.|Norwegian Institute of Public Health, Oslo, Norway.
Unni
U
Gopinathan
Chatham House Centre for Global Health Security, London, United Kingdom.|DRIVE-AB, Innovative Medicines Initiative, Geneva, Switzerland.
Charles
C
Clift
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.|ReAct - Action on Antibiotic Resistance, Uppsala, Sweden.
Anthony D
AD
So
DRIVE-AB, Innovative Medicines Initiative, Geneva, Switzerland.|London School of Economics, London, United Kingdom.
Chantal M
CM
Morel
Chatham House Centre for Global Health Security, London, United Kingdom.|DRIVE-AB, Innovative Medicines Initiative, Geneva, Switzerland.|Norwegian Institute of Public Health, Oslo, Norway.|University of Oslo, Oslo, Norway.|Harvard School of Public Health, Boston, Massachusetts, United States of America.
John-Arne
JA
Røttingen
D000900:Anti-Bacterial Agents; D003132:Commerce / Q000191:economics*; D004345:Drug Industry / Q000191:economics*; D007449:Investments; D008962:Models, Theoretical; D000071220:Pharmaceutical Research / Q000191:economics*
D000900:Anti-Bacterial Agents